<DOC>
	<DOCNO>NCT00318266</DOCNO>
	<brief_summary>It hypothesize NMP22 ( Nuclear Matrix Protein ) Bladder Check ® Test demonstrate improve sensitivity standard urine cytology patient superficial transitional cell carcinoma high risk recurrence .</brief_summary>
	<brief_title>NMP22 Provides Improved Sensitivity Detecting Bladder Cancers .</brief_title>
	<detailed_description>Patients previously treat bladder cancer high risk recurrence monitor recurrence every 3 month urine cytology cystoscopy part standard care.The NMP22 Bladder Cancer ® Test Kit design provide alternative regular urine cytology . A urine sample provide divided portion use ass NMP22 test kit remain sample sent lab regular urine cytology . Patient chart review medical student record age , clinical stage , pathologic stage , time disease progression/recurrence , site recurrence survival data .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>· History pTis , pT1 , large ( &gt; 2cm ) pTa multiple pTa bladder cancer tumour . Written Informed Consent prior studyrelated procedure . History bladder cancer tumour list inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Detection Bladder Cancer use NMP22 Urine Test Kit</keyword>
</DOC>